Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
|
|
- Timothy Patterson
- 5 years ago
- Views:
Transcription
1 WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black Country Partnership Foundation Trust (BCPFT) Pharmacy staff Medicines no longer required which have been dispensed by the SLA Pharmacy provider and transferred with the patient, not leaving hospital premises, and still in date, may be recycled. Any medicines that are no longer required and cannot be recycled MUST be disposed of in the appropriate pharmacy waste bin (Please see the Trust s up to date waste policy for the appropriate coloured lidded bin. Appendix A is a list of Hazardous medicines that extra care is needed with). This includes Patient s Own Drugs (PODs) only after completion of Patients Own Medicines Destruction Consent Form. See Standard Operating No. using Patients own Drugs. : 1. At each trolley/caddy check, medicines no longer required which have been supplied by BCPFT, must be removed from either the patient caddy or the medicines trolley. If this medication has not left the hospital premises and been supplied by the SLA Pharmacy Provider, it may be recycled for use by another patient, if found in suitable condition. Check that the medication is in date and suitable for use. Put into pharmacy pre-integrity checking box/drawer in pharmacy for later use and do not remove the dispensed label. The box/drawer containing the drugs for recycling in pharmacy needs to be emptied on a regular basis. Each medicine needs to be integrity checked by a band 5 technician or above (checking the medicine is in date and establishing its safety and suitability for re-use). Once the integrity check has been completed the medicine can then be placed into the post integrity checked receptacle/drawer and the medicines can then be accessed by the band 3 pharmacy assistant and booked into the folder and secured in the medicine cupboards for future use.
2 WARDS/DEPARTMENT By: 0 01/09/019 of 3. Enter the following details in the Stock Control folder on the appropriate alphabetised sheet:- Date The ward the medicine has been returned from (if available) Drug name (including strength and form) Quantity Batch number and expiry date 3. After booking in, store the medication in alphabetical order in the cupboard (all medication must be stored in the lockable medicine cupboard and not left in the office). Medicines must be used in date order. 4. When re-issuing medication, find the correct entry in the Stock Control folder and book out the item by completing the Date and issued to box on the log sheet. 5. If and when this item of medication is required for use for another patient or for ward use then apply a new label over the old label before issuing to the ward (apply new label without covering the name and address of original provider) 6. Any out of date medicines, medicines not suitable for use and PODs no longer required by the patient should be disposed of on the wards/department by placing in their original packaging into the appropriate pharmacy waste bin. 7. Make sure hazardous medicines go into the appropriate waste bin. 8. Patient s own medication no longer required may be disposed of after completion of Disposal of Patient s own Medicines Form (Refer to Sop No using Patients Own Drugs). The completed form must then be filed in the patient s notes, or in the pharmacy if notes have been filed. 9. At the end of each month the costing for all medicines recycled needs to be totalled. This establishes the savings the pharmacy department have made. Working through the recycling folder a list can be made of each medication recycled and the quantity recycled. 10. Once the list of names of medication and quantities have been logged down on a piece of paper somewhere then you need to access the Drug Tariff on line.
3 WARDS/DEPARTMENT By: 0 01/09/019 3 of 3 To access the Drug Tariff online you need to open the following link and scroll down to the appropriate month. Open up the Adobe PDF file and on the left hand side of page and scroll down to the link Part VIIIA Basic Prices of Drugs. Expand the link. Once the page has opened scroll down to your required medication the price quoted will be for an original pack size so take precaution to work out the sum if a part pack was recycled. For example Lansoprazole 30mg for a pack of 8 is 3.48 so if 1 was recycled you would use the sum = 0.14 x 1 =.60
4 Appendix A. Taken from the Safe Management of Healthcare Waste 1 This list is not exhaustive and may not include all very new, unlicensed or trial medicines List of Hazardous medicines. Aldesleukin Dactinomycin Alemtuzumab Danazol Alitretinoin Daunorubicin Hcl Altretamine Dasatinib Amsacrine Denileukin Anastrazole Dienestrol Arsenic trioxide Diethylstilbestrol Asparaginase Dinoprostone Azacitidine Dithranol Azathioprine Docetaxel Bacillus Calmette-Guerin Vaccine Doxorubicin Bexarotene Dutasteride Bicalutamide Epirubicin Bleomycin Ergometrine/methylergometrine Bortezomib Estradiol Busulfan Estramustine phosphate sodium Capecitabine Estrogen-progestin combinations Carboplatin Estrogens, conjugated Carmustine Estrogens, esterified Cetuximab Estrone Cetrorelix Acetate Estropipate Chlorambucil Etoposide Chloramphenicol Exemestane Chlormethine hydrochloride Finasteride Choriogonadotropin alfa Floxuridine Cidofovir Fludarabine Coal tar containing preps Fluorouracil Cisplatin Fluoxymesterone Cladribine Flutamide Colchicine Fulvestrant Ciclosporin Ganciclovir Cyclophosphamide Ganirelix acetate Cytarabine Gemcitabine Dacarbazine Gemtuzumab ozogamicin Goserelin Hydroxcarbamide
5 Cont. Ibritumomab tiuxetan Raloxifene Idarubicin Raltitrexed Ifosfamide Ribavirin Imatinib mesilate Rituximab Interferon containing products (including peginterferon) Sirolimus Irinotecan HCL Streptozocin Leflunomide Tacrolimus Letrozole Tamoxifen Leuprorelin acetate Temozolomide Lomustine Teniposide Megestrol Testolacton Menotropins Testosterone Mercaptopurine Thalidomide Melphalan Tioguanine Methotrexate Thiotepa Methyltestosterone Toremifene citrate Mifepristone Topotecan Mitomycin Tositumomab Mitotane Tretinoin Mitoxantrone HCL Trifluridine Mycophenolate mofetil Trimetrexate glucuronate Nafarelin Triptorelin Nilutamide Uramustine Oestrogen containing products Valganciclovir Oxaliplatin Valrubicin Oxytocin Vidarabine Paclitaxel Vinblastine sulphate Pegaspargase Vincristine sulphate Pentamidine isethionate Vindesine Pentostatin Vinorelbine tartrate Perphosphamide Zidovudine Pipobroman Piritrexim isethionate Plicamycin Podoflilox Podophyllum resin Prednimustine Procarbazine Progesterone Progestins
Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationPHARMACY PEARLS CHANIN WRIGHT, PHARMD
PHARMACY PEARLS CHANIN WRIGHT, PHARMD OBJECTIVES From the pearls heard, discuss with someone near you What is something you can apply to your setting Traumatic brain injury in children Goals Correct and
More informationHazardous Medication List
Hazardous Medication List REDUCING OCCUPATIONAL EXPOSURE TO HAZARDOUS MEDICATION FOR ALL STAFF Table of Contents Hazardous Medication List Key Points... 1 Hazardous Medication List... 2 Special Handling
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationDRUG PROPERTIES YOU NEED TO KNOW
jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationDRUGS YOU NEED TO KNOW
jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL
More information1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000
ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Characterization of the generated hipsc lines a) Western blot analysis indicating the efficient downregulation of p53 upon knockdown in three hipsc lines (
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationTitle Developed By. Implementation Contact person(s) Review Date Group Responsible. NICaN Policy: Management of Chemotherapy Extravasation; Version 3
Title Developed By Management of Chemotherapy Extravasation NICaN Regional Pharmacy Group Version History Version 3: 2009 (See appendix 6) Version 2: January 2006 Version 1: June 2005 Consultation Period
More informationFormulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationExposure Control Plan for Cytotoxic Substances
Exposure Control Plan Department of www.rms.ubc.ca UBC-RMS-OHS-ECP-17-001 Effective date: December 8, 2017 Review date: NA Supersedes: NA 1. PURPOSE Exposure Control Plan for Cytotoxic Substances The University
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationCHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS
CHEMOTHERAPY/ 1 Oncology, Misc, Vaccines ANTICANCER DRUGS/ NEOPLASTIC AGENTS Important Terms: Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationMABCAMPATH mg 3 INJ GENZYME BIOPHARMACEUTICALS. MABCAMPBATH mg 3 INJ GENZYME BIOPHARMACEUTICALS
ICON Formulary - November 2016 Class Medicine Name Nappi Strength Form Size Route Manufacturer Abiraterone Acetate ZYTIGA 250 720690001 250 mg 120 ORAL JANSSEN PHARMACEUTICALS Aldesleukin CHIRON IL-2 18
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationChemotherapy 101 for Radiation Oncology Workers
Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent
More informationECN Protocol Book. Guidelines on the management of extravasation. ECN_Protocol_Book_extravasation guidelines_2
ECN Protocol Book Guidelines on the management of extravasation Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationHCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1
drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More information1 SpringerWienNewYork
1 SpringerWienNewYork I. Mader, P. R. Fürst-Weger, R. M. Mader, E. Nogler-Semenitz, S. Wassertheurer Extravasation of Cytotoxic Agents Compendium for Prevention and Management Second edition SpringerWienNewYork
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationIntroduction to Antineoplastic Prescribing
Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationFOR A HIGHER DEGREE OF CONFIDENCE
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS. > Introduction Manufacturing specialized products in a pharmaceutical manufacturing environment has a specific set of requirements
More information8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
More informationVasco OP Underglove Sterile Surgical and Protective Gloves
data sheet EN 374:2003 EN 374:2003 AQL 0.65 B. Braun Melsungen AG confirms that Vasco OP Underglove gloves comply with the following standards and directives: EC CERTIFICATES AND Applied standards Medical
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationREVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Pediatr Blood Cancer 2011;57:191 198 REVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients L. Lee Dupuis, MScPhm, ACPR, FCSHP,
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationRecognising and reducing the risk of chemotherapy extravasation
Recognising and reducing the risk of chemotherapy extravasation When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future
More informationGuidelines for the Management of Extravasation (Version 5 May 2012)
Guidelines for the Management of Extravasation (Version 5 May 2012) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT NECDAG
More informationAdditional information to support. The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines
Additional information to support The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines Reference: NPSA/2008/RRR001 - issued on 22 January 2008
More informationChemotherapy extravasation guideline
Chemotherapy extravasation guideline. written by: WOSCAN Cancer Nursing and Pharmacy Group date written: September 2009 approved by: West of Scotland Cancer Advisory Network Clinical Leads Group review
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationONCOLOGY AND HAEMATOLOGY TREATMENT CENTRE Quality System Guidelines For The Safe Delivery of Systemic Anti Cancer Therapy
Title Document Type Issue no Safe Delivery of Systemic Anti-Cancer Therapy Guideline Clinical Governance Support Team Use Issue date May 2014 Review date May 2016 Distribution Prepared by Developed by
More informationVasco OP Free Sterile Surgical and Protective Gloves
DATA SheeT EN 374:2003 EN 374:2003 AQl 0.65 B. Braun Melsungen AG confirms that Vasco OP Free gloves comply with the following standards and directives: ec certificates AnD APPlieD STAnDArDS Medical device
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationVasco OP Sensitive Sterile Surgical and Protective Gloves
data sheet EN 374:2003 EN 374:2003 AQL 0.65 B. Braun Melsungen AG confirms that Vasco OP Sensitive gloves comply with the following standards and directives: EC CERTIFICATES AND Applied standards Medical
More informationAn introduction to the Essential Medicines concept: balancing innovation with public health priorities
An introduction to the Essential Medicines concept: balancing innovation with public health priorities WHO HQ, Geneva 11 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the Selection and
More informationGuidelines for the Management of Extravasation
Guidelines for the Management of Extravasation (Version 5.5-04 Nov 2016) Quality and safety for every patient every time Document Control Prepared By Chemo Nurse Group Chemo Nurse Group/ South Tees FT
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationCytostatics Definition, Terminology
Dept. of Pharmacology, Faculty of Medicine, Masaryk University in Brno Cytostatics Notes for Pharmacology II Practicals This study material is exclusively for students of general medicine and dentistry
More informationSELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS
SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS Manufacturing specialized products in a pharmaceutical
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationGuidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION
Guidelines for prevention and management of CHEMOTHERAPY EXTRAVASATION Please note that this policy refers to the management of extravasation of cytotoxic chemotherapy only. Refer to local Trust policies
More informationDisclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015
Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a
More informationSystemic Anticancer Therapy Drug Interactions Table
Systemic Anticancer Therapy Drug Interactions Table 1 This guide is intended to cover the most common interactions involving Systemic Anticancer therapies, e.g. cytotoxic agents, monoclonal antibodies
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT
CHEMOTHERAPY NETWORK GROUP POLICY FOR THE MANAGEMENT OF ETRAVASATION Policy for the management of extravasation Contents Page number Introduction 3 Definition 3 Prevention 3 Follow up 6 Signs and symptoms
More informationINDEX. Note: Page numbers followed by f indicate figures; page numbers followed by t indicate tables.
A ABV regimen, in Kaposi's sarcoma, 363-364 ABVD regimen, in Hodgkin's disease, 304t, 304-306, 308-310 AC regimen, in breast cancer, 113, 122 Accutane See Retinoids Acetaminophen, in palliative care, 368,
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Review Article Cytotoxic drug: Towards safer chemotherapy practices Joshi MC Clinical Pharmacologist, Prescription Audit Department, Indraprastha Apollo Hospital, Delhi Mathura Road, Sarita Vihar, New
More informationOvarian Cancer. compendia TREATMENT OF
drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management
More informationForm 2023 R2.0: Ovarian Cancer Pre-HSCT Data
Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More information